

Efficacy and safety of stem cells in the treatment of ischemic stroke A meta-analysis

Yu Xiong, MD^a, Xiumei Guo, MD^a, Wen Gao, MD^a, Chuhan Ke, MD^a, Xinyue Huang, MD^a, Zhigang Pan, MD^a, Chunhui Chen, MD^a, Hanlin Zheng, MD^a, Weipeng Hu, MD^a, Feng Zheng, MD^a, Hao Yao, MD^{b,*}

Abstract

Background: Stem cell therapy on ischemic stroke has long been studied using animal experiments. The efficacy and safety of this treatment in ischemic stroke patients remain uncertain.

Methods: We searched for all clinical randomized controlled trials published before October 2023, on PubMed, EMBASE, and the Cochrane Library using predetermined search terms, and performed a meta-analysis of the efficacy of stem cell therapy in ischemic stroke patients.

Results: 13 studies that included 592 ischemic stroke patients were reviewed. The mRS (MD -0.32, 95% Cl -0.64 to 0.00, $l^2 = 63\%$, P = .05), NIHSS (MD -1.63, 95% Cl -2.69 to -0.57, $l^2 = 58\%$, P = .003), and BI (MD 14.22, 95% Cl 3.95-24.48, $l^2 = 43\%$, P = .007) showed effective stem cell therapy. The mortality (OR 0.42, 95% Cl 0.23-0.79, $l^2 = 0\%$, P = .007) showed improved prognosis and reduce mortality with stem cell therapy.

Conclusion: Stem cell therapy reduces mortality and improves the neurological prognosis of ischemic stroke patients. However, due to the different types of stem cells used and the limited data in the reported studies, the safety of clinical applications of stem cells in patients with ischemic stroke must be carefully evaluated. Future randomized controlled trials with large sample sizes from controlled cell sources are warranted to validate this finding.

Abbreviations: BI = Barthel index, mRS = modified Rankin scale, MSCs = mesenchymal stem cells, NIHSS = National Institutes of Health Stroke Scale, RCT = randomized controlled trial.

Keywords: ischemic stroke, meta-analysis, mortality, randomized controlled trials, stem cells

1. Introduction

Ischemic stroke due to cerebral ischemia and hypoxia is a cerebrovascular disease with a high rate of disability. Ischemic stroke represents the main cause of disability and death worldwide.^[1] The mortality rate of ischemic stroke within 30 days has been reported to range from 5% to 15%, and the disability rate may exceed 50%.^[2,3] More than 40% of survivors experience ischemic stroke again, with even higher mortality and disability rates.^[2,4] To date, recombinant tissue plasminogen activator standard intravenous thrombolytic therapy represents the only clinically approved drug therapy for acute cerebral infarction. However, this treatment has limitations, mostly linked to its application within a short window period of 4.5 hours following onset of symptoms.^[5-7] Endovascular interventional therapy is also being increasingly used, but remains only applicable to patients with large vascular

occlusions.^[8,9] The disability rates for patients not eligible for either thrombolytic therapy or thrombectomy are even higher. Although rehabilitation treatment contributes to the recovery of neurological function, its curative effect remains limited.^[10,11]

To date, a large number of preclinical studies have shown that stem cells can improve the recovery of neurological function after a cerebral ischemic injury through a variety of mechanisms. This includes the inhibition of inflammation, promotion of axonal regeneration, and neuroprotective effects.^[12-19] Nevertheless, there have been few clinical trials on the treatment of ischemic stroke with stem cells.^[20] In this study, we conducted meta-analyses of previously published clinical randomized controlled trials to determine the efficacy and safety of stem cells in the treatment of ischemic stroke.

YX, XG, WG, and CK contributed equally to this work.

The authors have no funding and conflicts of interest to disclose.

Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Xiong Y, Guo X, Gao W, Ke C, Huang X, Pan Z, Chen C, Zheng H, Hu W, Zheng F, Yao H. Efficacy and safety of stem cells in the treatment of ischemic stroke: A meta-analysis. Medicine 2024;103:12(e37414).

Received: 30 November 2023 / Received in final form: 4 January 2024 / Accepted: 7 February 2024

http://dx.doi.org/10.1097/MD.000000000037414

The datasets generated during and/or analyzed during the current study are publicly available.

Supplemental Digital Content is available for this article.

^a Department of Neurosurgery, the Second Affiliated Hospital, Fujian Medical University, Quanzhou, China, ^b Department of Neurosurgery, Jinjiang Municipal Hospital, Quanzhou, China.

^{*} Correspondence: Hao Yao, Department of Neurosurgery, Jinjiang Municipal Hospital, Quanzhou, China (e-mail: 1536143277@qq.com).

2. Materials and methods

2.1. Search strategy

Two researchers (Y.X and F.Z) independently searched the PubMed, EMBASE, and Cochrane Library databases for any clinical randomized controlled trials published before October 2023. Keywords used in the search strategies included "stem cells," "ischemic stroke," and "randomized controlled trials" (MeSH and Entry Terms). The keywords used in this search strategy included "Randomized Controlled Trial" AND ("Progenitor Cells" OR "Mother Cells" OR "Colony-Forming Unit" OR "Stem Cells") AND ("Ischemic Stroke" OR "Cryptogenic Ischemic Stroke" OR "Cryptogenic Stroke" OR "Cryptogenic Embolism Stroke" OR "Wake-up Stroke" OR "Acute Ischemic Stroke" OR "Ischemic Stroke"). Repeated literature, case reports, summary meetings, animal experiments, other reviews and meta-analyses, ongoing experiments, and failed experiments were excluded for various reasons. Prior to the final data analysis, we ran a search algorithm for any new relevant publications. A flow chart of the specific search strategy is included in Figure 1 (Appendices Figures). The review was not registered. Ethical approval is not used for this study.

2.2. Inclusion criteria and exclusion criteria

The inclusion criteria of the eligible studies were as follows: ischemic stroke was diagnosed by computed tomography or magnetic resonance imaging (regardless of whether the disease was acute or chronic); intervention was stem cell therapy (regardless of type, dose, and injection mode); outcome indicators were the National Institutes of Health Stroke Scale (NIHSS), modified Rankin scale (mRS), Barthel index (BI), and safety results, including mortality and other complications; and the study was a clinical randomized controlled trial (RCT).

The exclusion criteria were as follows: interventions were not stem cells; other diseases; outcome indicators did not meet; only one group of data available or data could not be extracted or the data were incomplete; and follow-up failed due to various reasons.

2.3. Study selection

Two researchers (Y.X and F.Z) preliminarily screened studies that met the inclusion criteria according to the title and summary of the study. The full text of the preliminary study was then retrieved to assess whether they qualified for inclusion. Discrepancies were resolved through discussions.

2.4. Data extraction

Researcher Y.X used the pre-designed standardized form to extract data and the data was checked by the second researcher (F.Z) to evaluate the bias risk and evidence quality of individual included studies. The extracted information included the study country, study type, details of interventions, specific classification of diseases, treatment methods, outcome indicators, and other data u sed to assess the risk of bias and quality of evidence. Whenever possible, missing data were obtained by directly emailing the study authors.

2.5. Assessment quality

The Cochrane Risk Bias Assessment Tool was used to assess the bias of each study. The degree of bias risk (low risk, unknown risk, high risk) was evaluated from 7 aspects (random sequence generation, allocation concealment, blinding researchers and participants, integrity of outcome data, blind evaluation of research outcome, selective reporting of research result, and other sources of bias), so as to reflect the quality of each research.

2.6. Outcome measures

Mortality was the primary outcomes. The secondary outcomes included mRS, mRS \leq 2, NIHSS, BI, and related complications. Patients with mRS \leq 2 are generally considered to be non-disabling stroke patients with good prognosis.^[21]



Table 1

The characteristics of the 13 included studies.

Author	Country	Year	Age	Туре	Blind	Immuno- suppressive treatment	Rehabilitation	Stem cell group	Control group (Saline)	Cell type	Route of administration	Outcomes scale
Bang ^[24]	Korea	2012	30-75	Phase III	Yes	NR	NR	5	25	Autologous MSCs	Intravenous Injection	BI, mRS
Bhasin ^[25]	India	2016	33-61	NR	Incomplete	NR	Yes	10	10	Autologous MNCs	Intravenous Injection	SAE, mBI, FM, VEFG, MRC, BDNF
Bhatia ^[26]	India	2018	20-80	NR	Yes	NR	NR	10	10	Autologous MNCs	Arterial Injection	mRS, NIHSS, SAE
Chen ^[27]	CHINA	2014	35-75	Phase II	NR	NR	Yes	15	15	PBSC	NR	NIHSS, mRS
Chung ^[28]	Korea	2021	30-75	Phase II	Yes	NR	Yes	39	15	Autologous MSCs	Intravenous Injection	mRS, SAE, MI, FMA, FAC
Fang-1 ^[29]	CHINA	2018	18-80	Phase I/IIa	Incomplete	NR	NR	5	6	Autologous EPCs	NR	BI, mRS, NIHSS, SAE, SSS
Fang-2 ^[29]	CHINA	2018	18-80	Phase I/IIa	Incomplete	NR	NR	5	6	Autologous MSCs	NR	BI, mRS, NIHSS, SAE, SSS
Hess ^[30]	England USA	2017	18-83	Phase II	Yes	NR	NR	65	61	Allogenic MAPCs	Intravenous Iniection	mRS, NIHSS, BI, SAE
Jaillard ^[31]	France	2020	18-70	NR	Incomplete	NR	Yes	16	15	Autologous MSCs	Intravenous	NIHSS, mRS, BI, SAF_FMS
Jin ^[35]	CHINA	2017	NR	NR	NR	NR	NR	10	10	Autologous MNCs	NR	NIHSS, BI, mRS, SAF, FIM
Lee ^[32]	Korea	2010	30-75	NR	Incomplete	NR	NR	16	36	Autologous MSCs	Intravenous Injection	mRS, SAE, SDF-1a
Prasad ^[21]	India	2014	18-75	Phase II	Yes	NR	NR	60	60	Autologous MNCs	Intravenous	mRS, BI, NIHSS, IV
Savitz ^[33]	USA	2019	30-83	Phase II	Yes	NR	NR	29	16	Autologous BM ALD-401 cell	Arterial Injection	mRS, BI, NIHSS, SAF, DWL ALDH
Xie ^[34]	CHINA	2016	45-71	NR	NR	NR	NR	12	10	Allogeneic	NR	SAE, MMSE, HAMA, HBSD, UPDBS

ALDH = aldehyde dehydrogenase, BDNF = brain-derived neurotrophic growth factor, BI = Barthel index, DWI = diffusion-weighted imaging, EPCs = endothelial progenitor cells, FAC = functional ambulatory category, FIM = functional independence measure, FM = Fugl Meyer scale, FMA = Fugl-Meyer Assessment, FMS = Fugl-Meyer Score, HAMA = Hamilton Anxiety Rating Scale, HRSD = Hamilton Rating Scale for Depression, IV = infarct volume, MAPCs = multipotent adult progenitor cells, MI = motricity index, MMSE = mini-mental state examination, MNCs = marrow mononuclear cells, mRS = modified Rankin Scale, MSCs = mesenchymal stem cells, SAE = severe adverse events, SDF-1a = stromal cells derived factor-1a, SSS = Scandinavia Stroke Scale, UCMSCs = umbilical cord mesenchymal stem cells, UPDRS = Unified Parkinson's Disease Rating Scale, VEGF = vascular endothelial growth factor.

2.7. Statistical analyses

The meta-analysis of data was carried out using the REVMAN software. We obtained the 95% CI and P value of each study by measuring the MD of the continuous variable and the OR of the binary variable. Q-value statistics and I^2 value statistics were used to assess the heterogeneity of the study. According to the recommendations of the Cochrane Statistical Methods Group, the heterogeneity P value was set to .1, and the I^2 statistic was interpreted as: 0% to 40%-low heterogeneity, 30% to 60%-moderate heterogeneity, 50% to 90%-substantive heterogeneity, 75% to 100%-obvious heterogeneity. If there was substantial heterogeneity ($I^2 \ge 50\%$), researchers performed a sensitivity analysis or created a Galbraith plot (STATA) to identify the source of heterogeneity.^[22] For the outcome indicators of more than 10 patients, researchers developed a funnel plot (STATA) to assess publication bias.^[23] Egger and Begg's test was used to evaluate the asymmetry of the funnel plot, and a value of P > .05 was considered reflective of the absence of any publication bias.

3. Results

3.1. Search results

A total of 264 studies were identified using the search method, and 210 articles were included after removing duplicate articles. Another 136 articles were excluded during primary screening (because they were unrelated to the ailments studied or were meta-analyses, reviews, conference summaries, or animal experiments). Following a full review of the remaining 74 studies, 31 ongoing studies and 30 failed studies were excluded for various reasons (due to withdrawal of a large number of participants during the experiment and insufficient recruitment). The retrieval strategy was repeated before data analysis, and no additional studies were identified in the update. Finally, 13 studies^[21,24-35] involving 592 patients were included. The overall characteristics of the 13 studies and specific information on the individual studies are represented in detail in Table 1

3.2. Risk of bias in included studies

The Cochrane risk bias assessment tool was used to assess the quality of the included 13 RCTs. Among these, 11 studies^[21,24-32,35] specified the process of generating random sequences, including random number tables, computer random number generation, coin throwing, and double-blind lottery. Two studies did not specify the randomization process.^[33,34] Six studies^[24-26,30,33,35] mentioned blindness for participants and major researchers, and 2 studies^[27,29] only considered single blindness. Four studies^[21,31,32,34] were not blinded to the researchers or participants (open label) and one study^[28] did not elaborate on blindness. There were follow-up losses in the 13 studies; due to the small number of missing follow-ups, the number was balanced between groups, which was insufficient to impact the intervention effect. The results of the bias risk assessment are represented in Figures S1 and 2, Supplemental Digital Content, http://links.lww.com/MD/L843; http://links.lww.com/MD/L870 (Appendices Figures).

3.3. Outcomes

We included a total of 13 studies (Fang's study used 2 cell types; Fang-1 and Fang-2), of which mesenchymal stem cells (MSCs) were reported in 6,^[24,28,29,31,32,34] marrow mononuclear cells (MNC) in 4,^[21,25,26,35] peripheral blood stem cells in 1,^[27] endothelial progenitor cells in 1,^[29] multipotent adult progenitor cells in 1,^[130] and ALD-401 cells in 1.^[33] Included studies were divided into the "MSCs" group, "MNCs" group and "Other" group, and we performed subgroup analysis based on the different stem cell types.

3.3.1. *Mortality.* At the end of the follow-up period, 13 studies^[21,24-32,35,36] reported the number of deaths, and the data showed that the mortality in the stem cell intervention group was lower than that in the control group (OR 0.42, 95% CI 0.23–0.79, $I^2 = 0\%$, P = .007, Fig. 2B). Our subgroup analysis revealed that MSCs (OR 0.25, 95% CI 0.07–0.83, $I^2 = 0\%$, P = .02) and other types of stem cells (OR 0.33, 95% CI 0.12–0.88, $I^2 = 0\%$, P = .03) had a significant effect on the mortality in patients with ischemic stroke, while MNCs (OR 0.88, 95% CI 0.30–2.58, $I^2 = 0\%$, P = .82) had no significant effect on mortality (Fig. 2B).

3.3.2. *mRS*. The mRS scores at the end of the follow-up were reported in 10 studies.^[21,24,26-32,35] The data showed that stem cell intervention had a beneficial trend for patients with ischemic stroke (MD –0.32, 95% CI –0.64, 0.00, I^2 = 63%, P = .05, Fig. 3A). Based on different stem cell types, subgroup analysis showed that MSCs (MD –0.10, 95% CI –0.42, 0.22, I^2 = 0%, P = .55), MNCs (MD –0.57, 95% CI –1.58, 0.44, I^2 = 83%, P = .27), and other types of stem cells (MD –0.32, 95% CI –0.91, 0.28, I^2 = 80%, P = .30) had no significant effect on mRS scores in patients with ischemic stroke (Fig. 3A). Statistically, there was significant heterogeneity between studies (I^2 > 50%), and the analysis by Galbraith diagram showed that 2 studies^[27,35] significantly contributed to heterogeneity (Figure S3, Supplemental Digital Content, http://links.lww.com/MD/L844) (Appendices Figures).

3.3.3. *mRS* \leq **2.** Four studies^[21,28,30,32] reported an mRS \leq 2 score at the end of follow-up. There was no significant difference between the stem cell intervention group and the control group (OR 1.07, 95% CI 0.67–1.73, $I^2 = 0\%$, P = .77, Fig. 3B). Based on different stem cell types, subgroup analysis showed that MSCs (OR 0.66, 95% CI 0.19–2.27, $I^2 = 0\%$, P = .51), MNCs (OR 1.31, 95% CI 0.63–2.73, P = .46), and other types of stem cells (OR 1.04, 95% CI 0.50–2.14, P = .92) had no significant effect on ischemic stroke patients with mRS \leq 2 (Fig. 3B).

NIHSS. NIHSS scores were reported in 3.3.4. studies^[21,26,27,29-31,34,35] at the end of the follow-up. Significant differences were detected between the 2 groups in favor of stem cell intervention (MD -1.63, 95% CI -2.69 to -0.57, $I^2 = 58\%$, P = .003, Fig. 4A). Based on different stem cell types, subgroup analysis showed that MNCs had a significant effect on NIHSS score in patients with ischemic stroke (MD -1.68, 95% CI $-2.63, -0.72, I^2 = 0\%, P < .001$, while MSCs (MD -1.69, 95%CI $-3.81, 0.43, I^2 = 38\%, P = .12$) and other stem cell types (MD -1.57,95% CI $-4.81, 1.66, I^2 = 90\%, P = .34$) did not (Fig. 4A). Again, significant heterogeneity was observed between the included studies (P > 50%). A sensitivity analysis of the 8 studies found that heterogeneity decreased significantly with little effect on the pooled result, as summarized in Figure 3B (MD -2.02, 95% CI -2.96 to -1.08, $I^2 = 35\%$, P < .001, Fig. 4B).

3.3.5. *BI.* Five studies^[21,24,31,34,35] reported the BI scale at the end of the follow-up, and data showed that there was a significant difference in the BI scale favoring stem cell intervention (MD 14.22, 95% CI 3.95–24.48, $I^2 = 43\%$, P = .007, Fig. 2A). Subgroup analysis on different stem cell types showed that MSCs

(MD 9.74, 95% CI 0.15–19.33, $I^2 = 1\%$, P = .05) and MNCs (MD 24.20, 95% CI 11.57–36.83, P < .001) had a significant effect on BI score in patients with ischemic stroke (Fig. 2A).

3.3.6. Complications. Complications were recorded in the context of 13 studies^[21,24-35] at the end of the follow-up. Three studies^[25,27,34] reported no early or late complications during or after transplantation. The data showed that there was no significant difference in the incidence of complications between the stem cell intervention and control groups (OR 0.58, 95%) CI 0.21–1.63, $I^2 = 13\%$, P = .31, Fig. 5A). Among the studies included in the present meta-analysis, recurrent ischemic stroke or transient ischemic attack (TIA), infection, and seizures were the most common complications. Therefore, we further performed a subgroup analysis. The data showed that there was no significant difference in the incidence of recurrent ischemic stroke or TIA (OR 0.80, 95% CI 0.23–2.83, *I*² = 14%, *P* = .73, Fig. 5B), infection (OR 0.77, 95% CI 0.45–1.29, $I^2 = 0\%$, P = .32, Fig. 2B), and seizure (OR 1.09, 95% CI 0.41–2.90, I^2 = 6%, P = .86, Fig. 5B) between the treatment group and the control group. The specific complications in each study are represented in Table 2. Distribution of the complications is shown in Figure 6.

4. Discussion

In this study, 13 studies that met the inclusion criteria were assessed to evaluate the efficacy and safety of stem cells in the treatment of ischemic stroke by examining mortality, mRS, NIHSS, BI, and complications. The mRS, NIHSS, and BI scores are majorly used to evaluate the severity of ischemic stroke in the clinical setting, of which the mRS is utilized to evaluate the functional independence of patients, NIHSS to accurately assess the severity of neurological defects, and BI to evaluate the quality of daily life and the degree of disability.^[37] MRS \leq 2 was linked to patient prognosis.^[28] An mRS \leq 2 is considered to have an overall better prognosis in the absence of severe disability.

Overall, compared with the control group, stem cell treatment had a significant effect on patients with ischemic stroke (P < .05), which was manifested by a decrease in mortality in the stem cell intervention group and an improvement in mRS, NIHSS, and BI scores.

The mRS \leq 2 showed no significant difference across the stem cell intervention and control groups. However, different stem cell types were used in different studies, including MSCs, MNC, peripheral blood stem cells, endothelial progenitor cells, multipotent adult progenitor cells and ALD-401 cells. We divided the included studies into the "MSCs" group, the "MNCs" group, and "Other" group, and performed subgroup analysis on all the outcomes. Data analysis showed that the application of MSCs could improve the BI score of patients with ischemic stroke and reduce mortality but showed no effect on mRS and NIHSS scores. The application of MNCs can improve the NIHSS score and BI score of patients, but has no effect on mRS score and mortality. The application of stem cells from the "Other" group can reduce the mortality of patients but has no effect on mRS and NIHSS scores. The differences in results of the overall and subgroup analyses may be related to the different types of stem cells used, the different evaluation criteria of mRS, NIHSS, and BI scores, and the basic scores of the patient population. The factors owing to these differences should be explored further.

Complications are linked to many factors, including the severity of the disease, injection route of stem cells, type of stem cells, dose of stem cells, and duration of administration. Among the 411 reported complications, 1 study reported drug-related injuries (20 cases),^[30] 4 studies reported recurrent ischemic stroke (8 cases),^[28,29,31,32] 4 studies reported infection (67 cases),^[26,30,32] 1 study reported transient ischemic attack (1 case),^[28] and 2 studies reported epileptic seizures (10 cases),^[29,32] Subgroup analysis

	Ste	m Cell	I	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup 1.1.1 MSCs	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV. Random. 95% Cl
Lee 2010	4	1.6	16	4.6	1.9	36	6.8%	-0.60 [-1.60, 0.40]	
Jaillard 2020	3	0.63	16	3	0.66	15	14.7%	0.00 [-0.45, 0.45]	
Chung 2021	3.36	0.86	39	3.4	0.88	15	13.5%	-0.04 [-0.56, 0.48]	
Bang 2005	2.81	2.6	5	3.85	1.09	25	1.7%	-1.04 [-3.36, 1.28]	•
Subtotal (95% CI)			76			91	36.8%	-0.10 [-0.42, 0.22]	-
Heterogeneity: Tau [#] = Test for overall effect:	0.00; CI Z = 0.59	hi ^a = 1. I (P = 0	83, df= 1.55)	= 3 (P =	0.61);	I = 0%			
1.1.2 MNCs									
Prasad 2014	3.61	1.22	59	3.47	1.31	59	14.7%	0.14 [-0.32, 0.60]	
Jin 2017	1.2	0.4	10	2.3	0.8	10	12.9%	-1.10 [-1.65, -0.55]	
Bhatia 2018	1.3	1.8	10	2.3	2.2	10	2.8%	-1.00 [-2.76, 0.76]	-
Subtotal (95% CI)			79			79	30.4%	-0.57 [-1.58, 0.44]	
Heterogeneity: Tau ⁼ = Test for overall effect:	0.59; CI Z = 1.10	hi [¤] = 11 I (P = 0	1.93, d1 1.27)	f = 2 (P =	= 0.00	3); I ¤ = 8	33%		
1.1.3 Others		10.02121	122	2 2 2 1			1558	1727 212 13 1 1 1 2	
Hess 2017	2.8	1.32	67	2.79	1.25	62	15.0%	0.01 [-0.43, 0.45]	
Chen 2014	2.1	0.3	15	2.7	0.5	15	17.9%	-0.60 [-0.90, -0.30]	
Subtotal (95% CI)	045.0		82	10	0.001	17 000	32.9%	-0.32 [-0.91, 0.28]	
Heterogeneity: l'auf = Test for overall effect.	Z = 1.05	ni* = 5. 6 (P = 0	04, df = 1.30)	= 1 (P =	0.02);	L = 803	70		
Total (95% CI)			237			247	100.0%	-0.32 [-0.64, -0.00]	-
Heterogeneity: Tau ^a =	0.12; CI	hi" = 21	1.34, dt	(= 8 (P =	= 0.00	6); I = 6	63%		
Test for overall effect.	Z=1.97	(P=0	.05)						Eavours lexperimental Eavours (control)
Test for subaroup diff	erences	: Chi ² =	= 1.03.	df = 2 (P = 0.6	60). ² =	0%		a source texperimental a source (control)
0.1	Ster	m Cell		Contro	ol Traci	144	(Odds Ratio	Odds Ratio
124 MSCs	Even	IS 10		vents	rotal	weig	nt M-H,	Kandom, 95% Cl	M-H, Kandom, 95% Cl
1.2. I WSUS		G	20	2	10	6.0	OV.	0.741040.4551	
Chung 2021		4	39	2	15	6.9	70	0.74 [0.12, 4.55]	
Lee 2010		2	10	(30	1.9	70	0.59 [0.11, 3.23]	
Subtotal (95% CI)			55	1	51	14./	%	0.00 [0.19, 2.27]	
lotal events	0.00	6		9			0.04		
Heterogeneity: Tau* Test for overall effect	= 0.00; 0 t. Z = 0.6	Chi⁼= 66 (P =	0.03, c : 0.51)	1f = 1 (F	° = 0.8	6); I ^z =	0%		
1.2.2 MNCs	1.0	- 1101		C STREET,	1000	0.258			
Prasad 2014		29	57	26	59	42.4	%	1.31 [0.63, 2.73]	
Subtotal (95% CI)			57		59	42.4	%	1.31 [0.63, 2.73]	
Total events	1	29		26					
Heterogeneity: Not a Test for overall effect	pplicab t: Z = 0.7	le 73 (P =	0.46)						
1.2.3 Others									
Hess 2017	3.	24	65	22	61	42.9	%	1.04 [0.50, 2.14]	
Subtotal (95% CI)			65		61	42.9	%	1.04 [0.50, 2.14]	
Total events		24		22					
Heterogeneity: Not a	pplicab	le		1608735					
Test for overall effect	t: Z = 0.1	10 (P =	: 0.92)						
Total (95% CI)		1	77		171	100.0	%	1.07 [0.67, 1.73]	-
Total events	4	59		57					
				U 1					
Heterogeneity: Tau ²	= 0.00:	Chi ^z =	0.94. 0	1f = 3 (F	P = 0.8	2); ⁼=	0%	The part of the pa	
Heterogeneity: Tau ² : Test for overall effect	= 0.00; 0 t: Z = 0 2	Chi [≇] = 29 (P =	0.94, c 0.77)	lf = 3 (F	P = 0.8	l2); I ≇=	0%		0.2 0.5 1 2 5

Figure 2. Meta-analysis of the effect of stem cells on ischemic stroke with Barthel index (A). Meta-analysis of the effect of stem cells on mortality in patients with ischemic stroke (B).

of common complications, including recurrent ischemic stroke or TIA, infection, and seizure, showed that there was no significant difference between the experimental and control groups. Therefore, future studies should assess whether genetic charge affect the prognosis of patients following stem cell therapy. In addition, further research may focus on the reduction of the incidence of complications during stem cell transplantation, which currently remains a clinical challenge.^[38] Furthermore, the socioeconomic value and cost-effectiveness of stem cells in the treatment of ischemic stroke should also be evaluated, as the financial and social burden of the disease plays a prominent role in long-term outcomes.^[39]

Several preclinical animal experiments have demonstrated that stem cell transplantation following ischemic stroke may significantly improve neurological deficits.^[40,41] In addition to directly replacing cells, stem cells are associated with

Study or Subgroup	Mean	en cell	Total	Moor	en en	Total	Moint		Wedit Di	
SUUDY OF SUDGFOUP	mean	<u>50</u>	00	mean	50	10(3)	veight	IV, Kaliuolii, 95% Cl	IV, Rando	111, 95% CI
Z.1.1 MSCS	0		4.0			10	10.000	0.001.007.4.471		
Bhatia 2018	2	1.1	10	2.8	3.5	10	12.0%	-0.80 [-3.07, 1.47]		
Jaillard 2020	8.94	5.2	16	9.4	4.7	15	6.9%	-0.46 [-3.95, 3.03]		
XIe 2016	3.34	3.79	12	7.36	3.64	10	8.1%	-4.02 [-7.13, -0.91]		
Subtotal (95% CI)			38			35	27.0 %	-1.69 [-3.81, 0.43]		
Heterogeneity: Tau ² = Test for overall effect:	= 1.34; Cł : Z = 1.56	ni ^z = 3.2 (P = 0.	21, df = 12)	: 2 (P =	0.20);	 = 389	6			
2.1.2 MNCs										
Jin 2017	4.3	1.5	10	6.3	1.2	10	20.1%	-2.00 [-3.19, -0.81]		
Prasad 2014 Subtotal (95% CI)	4.8	4.1	60 70	5.9	4.8	60 70	16.7% 36.8 %	-1.10 [-2.70, 0.50] - 1.68 [-2.63, -0.72]		_
Heterogeneity: Tau ⁼ = Test for overall effect	= 0.00; Cł Z = 3.45	ni ⁼ = 0.7 (P = 0.1	78, df = 0006)	: 1 (P =	0.38);	I ¤ = 0%				
2.1.3 Others										
Chen 2014	5.5	1.8	15	8.7	1.9	15	18.9%	-3.20 [-4.52, -1.88]		
Hess 2017	4.3	4.33	67	4.2	4.46	62	17.3%	0.10 [-1.42, 1.62]		•
Subtotal (95% CI)			82			77	36.2%	-1.57 [-4.81, 1.66]		
Heterogeneity: Tau ² = Test for overall effect:	= 4.92; Ch Z = 0.95	ni ² = 10 (P = 0.	.30, df .34)	= 1 (P :	= 0.001); ² = 9	10%			
Total (95% CI)			190			182	100.0 %	-1.63 [-2.69, -0.57]		
Heterogeneity: Tau ⁼ =	= 1.09; Cł : 7 = 3.01	ni [∎] = 14 (P = 0	.33, df	= 6 (P :	= 0.03)	; I " = 58	3%	-		
Test for subaroup dif	ferences:	: Chi ² =	0.00.	df = 2 (1	² = 1.0	0), ² = (0%		Favours (experimental)	Favours (control)
Test for subaroup dif	ferences: Ste	: Chi ² = m Cell	0.00.	df = 2 (1 C	⊃ = 1.0 ontrol	0). ª = (0%	Mean Difference	Favours (experimental) Mean Di	fference
Test for subaroup dif	ferences: Ste Mean	: Chi ² = m Cell SD	0.00. Total	df = 2 (1 C Mean	° = 1.0 ontrol SD	0). ª = (Total	0% Weight	Mean Difference IV, Random, 95% Cl	Pavours (experimental) Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup 2.1.1 MSCs	ferences: Ste Mean	Thi ² = Thi ² = Thi ² = This This This This This This This This	0.00.	df = 2 (1 C <u>Mean</u>	° = 1.0 ontrol SD	0), ª = 1 Total	0% Weight	Mean Difference IV, Random, 95% Cl	Mean Di Nean Di	fference m. 95% Cl
Study or Subgroup 2.1.1 MSCs Bhatia 2018	ferences: Ste <u>Mean</u>	: Chi [≇] = m Cell <u>SD</u>	0.00.1 <u>Total</u>	df = 2 (1 C <u>Mean</u> 2 8	P = 1.0 ontrol <u>SD</u>	0). ² = 1 <u>Total</u> 10	0% <u>Weight</u> 12.7%	Mean Difference <u>IV, Random, 95% Cl</u>	Mean Di IV. Rando	fference m. 95% Cl
Study or Subgroup 2.1.1 MSCs Bhatia 2018	ferences: Ste Mean	(1 = 0. : Chi [₹] = m Cell <u>SD</u> 1.1 5.2	10.00.00	df = 2 (1 C <u>Mean</u> 2.8 9 4	P = 1.0 ontrol SD 3.5 4.7	0). ² = 1 <u>Total</u> 10	0% Weight 12.7%	Mean Difference IV, Random, 95% Cl -0.80 [-3.07, 1.47] -0.46 [-3.95, 2.02]	Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Via 2016	2 = 3.91 ferences: <u>Ste</u> <u>Mean</u> 2 8.94 3.34	: Chi [₽] = m Cell <u>SD</u> 1.1 5.2 3.79	10 10 10	df = 2 (f C <u>Mean</u> 2.8 9.4 7 36	P = 1.0 ontrol SD 3.5 4.7 3.64	0). ² = 0 <u>Total</u> 10 15 10	0% <u>Weight</u> 12.7% 6.4% 7.7%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 L7 13 -0.041	Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI)	2 = 3.91 ferences: <u>Mean</u> 2 8.94 3.34	(10 10 16 12 38	df = 2 (f C <u>Mean</u> 2.8 9.4 7.36	P = 1.0 ontrol SD 3.5 4.7 3.64	0). ² = 1 <u>Total</u> 10 15 10 35	Weight 12.7% 6.4% 7.7% 26.8%	Mean Difference <u>IV, Random, 95% Cl</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 L3 81 0 43]	Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² -	2 = 3.31 ferences: <u>Mean</u> 2 8.94 3.34	(r = 0. : Chi ² = m Cell <u>SD</u> 1.1 5.2 3.79	10 10 10 16 12 38 21 df	df = 2 (l C <u>Mean</u> 2.8 9.4 7.36	P = 1.0 ontrol <u>SD</u> 3.5 4.7 3.64 0.20):	0). ² = 1 <u>Total</u> 10 15 10 35 ² = 288	12.7% 6.4% 7.7% 26.8%	Mean Difference N, Random, 95% Cl -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43]	Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup dif Study or Subgroup dif 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect	2 = 3.31 ferences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ch : Z = 1.56	($\Gamma = 0.$: Chi ² = m Cell SD 1.1 5.2 3.79 hi ² = 3.2 ($P = 0.$	10 10 10 16 12 38 21, df = 12)	df = 2 (l C <u>Mean</u> 2.8 9.4 7.36 : 2 (P =	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20);	0). " = 1 <u>Total</u> 10 15 10 35 7 = 389	Weight 12.7% 6.4% 7.7% 26.8%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43]	Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs	2 = 0.01 ferences: Ste <u>8.94</u> 3.34 = 1.34; Ct Z = 1.56	$(P = 0.1)^{(1)}$ $(P = 0.1)^{(1)}$ $(P = 0.1)^{(1)}$	10 10 16 12 38 21, df = 12)	df = 2 (1 C <u>Mean</u> 2.8 9.4 7.36 : 2 (P =	P = 1.0 ontrol <u>SD</u> 3.5 4.7 3.64 0.20);	0). ² = <u>Total</u> 10 15 10 35 ² = 389	0% Weight 12.7% 6.4% 7.7% 26.8% %	Mean Difference IV, Random, 95% CI -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43]	Mean Di IV. Rando	fference m. 95% Cl
Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017	2 = 0.01 ferences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3	(r = 0.) $: Chi^2 =$ m Cell 5.2 3.79 $hi^2 = 3.2$ (P = 0.) 1.5	Total 10 10 16 12 38 21, df = 12) 10	df = 2 (1 C <u>Mean</u> 2.8 9.4 7.36 : 2 (P = 6.3	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2	0). " = <u>Total</u> 10 15 10 35 ² = 389 10	0% Weight 12.7% 6.4% 7.7% 26.8% 6 27.7%	Mean Difference N, Random, 95% Cl -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81]	Mean Di IV. Rando	fference m. 95% Cl
Test for subgroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014	rerences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8	(r = 0.) $: Chi^2 =$ m Cell 5.2 3.79 $hi^2 = 3.2$ (P = 0.) 1.5 4.1	10 10 10 16 12 38 21, df = 12) 10 60	df = 2 (1 C <u>Mean</u> 2.8 9.4 7.36 : 2 (P = 6.3 5.9	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8	0). ² = 1 <u>Total</u> 10 15 10 35 ² = 389 10 60	0% Weight 12.7% 6.4% 7.7% 26.8% 27.7% 20.4%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50]	Mean Di IV. Rando	fference m. 95% Cl
Test for subaroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% Cl)	Ferences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8	(P = 0.1) (P	10 10 16 12 38 21, df = 12) 10 60 70	df = 2 (1 C <u>Mean</u> 2.8 9.4 7.36 : 2 (P = 6.3 5.9	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8	0). ² = 1 <u>Total</u> 10 15 10 35 ² = 389 10 60 70	Weight 12.7% 6.4% 7.7% 26.8% % 27.7% 20.4% 48.1%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72]	Mean Di IV, Rando	fference m. 95% Cl
Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect	2 = 3.81 ferences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45	(r = 0.7) $(r = 0.7)$	Total 10 16 12 38 21, df= 12) 10 60 70 78, df= 0006)	df = 2 (f C <u>Mean</u> 2.8 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P =	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.38);	0). ² = 1 10 15 10 35 ² = 389 10 60 70 ² = 0%	0% Weight 12.7% 6.4% 7.7% 26.8% 6 27.7% 20.4% 48.1%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72]	Mean Di IV, Rando	fference m. 95% Cl
Test for subaroup dif Test for subaroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.3 Others	2 = 3.81 ferences: Ste Mean 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45	(P = 0.7) (P = 0.7)	Total 10 16 12 38 21, df = 12) 10 60 70 78, df = 0006)	df = 2 (f C <u>Mean</u> 2.8 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P =	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.38);	0). ² = 1 10 15 10 35 ² = 389 10 60 70 ² = 0%	0% Weight 12.7% 6.4% 7.7% 26.8% 6 27.7% 20.4% 48.1%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72]	Mean Di IV. Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.3 Others Chen 2014	2 = 3.81 ferences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45	(r = 0.1) $: Chi^2 = m Cell SD = 1.1 = 5.2 = 3.79 = 3.10 = 0.$	10 16 12 38 21, df = 12) 10 60 70 78, df = 0006)	df = 2 (f <u>C</u> <u>2.8</u> 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P = 8.7	<pre>> = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.38); 1.9</pre>	0). ² = 1 Total 10 15 10 35 ² = 389 10 60 70 ² = 0%	0% Weight 12.7% 6.4% 7.7% 26.8% 6 27.7% 20.4% 48.1% 25.0%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52] -1.88]	Mean Di IV, Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.3 Others Chen 2014 Hess 2017	2 = 3.81 ferences: Ste Mean 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45 5.5 4.2	$(C = 0)^{(1)} = (C = 0)^{(1)$	0.00.1 10 10 16 12 38 21, df = 12) 10 60 70 78, df = 0006) 15 67	df = 2 (f <u>C</u> <u>Mean</u> 2.8 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P = 8.7 4.2	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.39); 1.9 4.46	0). ² = 1 <u>Total</u> 10 15 10 35 ² = 389 10 60 70 ² = 0% 15 62	Weight 12.7% 6.4% 7.7% 26.8% % 27.7% 20.4% 48.1% 25.0% 0.9%	Mean Difference IV, Random, 95% CI -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62]	Mean Di IV, Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% CI)	2 = 3.81 ferences: Ste <u>Mean</u> 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45 5.5 4.3	(r = 0.1) + (r =	0.00.1 0.00.1 10 16 12 38 21, df = 12) 10 60 70 78, df = 0006) 15 67 75 75	df = 2 (f <u>C</u> <u>2.8</u> 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P = 8.7 4.2	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.39); 1.9 4.46	0). ² = 1 <u>Total</u> 10 15 10 35 1 ² = 389 10 60 70 ² = 0% 15 62 15 62 15	Weight 12.7% 6.4% 7.7% 26.8% 6 27.7% 20.4% 48.1% 25.0% 0.0% 25.0%	Mean Difference <u>IV, Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88]	Mean Di IV, Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% CI) Heterogeneity: Tau ² =	2 = 0.01 ferences: Ste Mean 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45 5.5 4.3 2 5.5 4.3	(r = 0) (c = 10) (c =	0.00.1 0.00.1 10 16 12 38 21, df = 12) 10 60 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 75 67 15 67 15 67 15 67 15 67 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15	df = 2 (f <u>C</u> <u>9.4</u> 7.36 2.8 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P = 8.7 4.2	^D = 1.0 ontrol <u>SD</u> 3.5 4.7 3.64 0.20); 1.2 4.8 0.38); 1.9 4.46	0). ² = 1 Total 10 15 10 35 1 ² = 389 10 60 70 1 ² = 0% 15 62 15	0% Weight 12.7% 6.4% 7.7% 26.8% 27.7% 20.4% 48.1% 25.0% 25.0%	Mean Difference <u>IV. Random, 95% CI</u> -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88]	Mean Di IV, Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% CI) Heterogeneity: Not ar Test for overall effect:	Z = 0.01 ferences: Ste Mean 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45 5.5 4.3 5.5 4.3 5.5 4.3	(P < 0.)	0.00.1 10 10 16 12 38 21, df= 12) 10 60 70 76, df= 0006) 15 67 15 000001	df = 2 (f <u>C</u> <u>9.4</u> 7.36 2.8 9.4 7.36 2.7 6.3 5.9 1 (P = 8.7 4.2)	^D = 1.0 ontrol <u>SD</u> 3.5 4.7 3.64 0.20); 1.2 4.8 0.38); 1.9 4.46	0). ² = 1 Total 10 15 10 35 ² = 389 10 60 70 ² = 0% 15 62 15 62 15	0% Weight 12.7% 6.4% 7.7% 26.8% 27.7% 20.4% 48.1% 25.0% 0.0% 25.0%	Mean Difference IV, Random, 95% CI -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88]	Mean Di IV, Rando	fference m. 95% Cl
Test for subaroup dif Study or Subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% Cl) Heterogeneity: Not agrees Test for overall effect: Subtotal (95% Cl) Heterogeneity: Not agrees Test for overall effect: Total (95% Cl)	$\frac{1}{2} = 3.81$ ferences: Ste Mean 2 8.94 3.34 = 1.34; Cf 2 = 1.56 4.3 4.8 = 0.00; Cf Z = 3.45 5.5 4.3 oplicable Z = 4.74	(P < 0) $(P < 0)$	10 10 10 16 12 38 21, df = 12) 10 60 70 70 70 70 70 15 67 15 000001 123	df = 2 (f C Mean 2.8 9.4 7.36 : 2 (P = 6.3 5.9 : 1 (P = 8.7 4.2)	^a = 1.0 ontrol <u>SD</u> 3.5 4.7 3.64 0.20); 1.2 4.8 0.38); 1.9 4.46	0). ² = 1 Total 10 15 10 35 ² = 389 10 60 70 ² = 0% 15 62 15 62 15 120	0% Weight 12.7% 6.4% 7.7% 26.8% 6 27.7% 20.4% 48.1% 25.0% 0.0% 25.0% 100.0%	Mean Difference N, Random, 95% CI -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88]	Mean Di IV. Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% Cl) Heterogeneity: Not a; Test for overall effect: 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% Cl) Heterogeneity: Not a; Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² =	$\frac{1}{2} = 3.51$ ferences: Ste Mean 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45 5.5 4.3 oplicable Z = 4.74	(P < 0) $(P < 0)$ $(P < 0)$	0.00.1 0.00.1 10 16 12 38 21, df= 12) 10 60 70 70 70 70 70 70 70 70 70 7	df = 2 (l) C Mean 2.8 9.4 7.36 $2 (P =6.35.91 (P =8.74.2)4.2$	P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.38); 1.9 4.46	0). ² = 1 Total 10 15 10 35 ² = 389 10 60 70 15 62 15 62 15 62 15 62 15 62 15 62 15 62 15 15 10 70 8 70 70 70 70 70 70 70 70 70 70	0% Weight 12.7% 6.4% 7.7% 26.8% 27.7% 20.4% 48.1% 25.0% 0.0% 25.0% 0.0% 25.0%	Mean Difference IV, Random, 95% CI -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88]	Mean Di IV, Rando	fference m. 95% Cl
Test for subgroup Test for subgroup 2.1.1 MSCs Bhatia 2018 Jaillard 2020 Xie 2016 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.2 MNCs Jin 2017 Prasad 2014 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.1.3 Others Chen 2014 Hess 2017 Subtotal (95% CI) Heterogeneity: Not ar Test for overall effect: Notal (95% CI) Heterogeneity: Not ar Test for overall effect: Total (95% CI) Heterogeneity: Not ar Test for overall effect: Total (95% CI) Heterogeneity: Tau ² =	Z = 0.81 ferences: Ste Mean 2 8.94 3.34 = 1.34; Ct Z = 1.56 4.3 4.8 = 0.00; Ct Z = 3.45 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 4.3 5.5 6.4, 3 6.4, 5, Ct	(P < 0) $(P = 7,, P)$ $(P = 7,, P)$ $(P = 0,, P)$	0.00.1 0.00.1 10 16 12 38 21, df= 12) 10 60 70 76, df= 00001 123 75, df=	df = 2 (f <u>C</u> <u>9.4</u> 7.36 2.8 9.4 7.36 2.7 6.3 5.9 1 (P = 8.7 4.2) 5 (P =	<pre>P = 1.0 ontrol SD 3.5 4.7 3.64 0.20); 1.2 4.8 0.38); 1.9 4.46</pre>	0). ² = 1 Total 10 15 10 35 ² = 389 10 60 70 1 ⁵ 62 15 62 15 62 15 120 ² = 359	0% Weight 12.7% 6.4% 7.7% 26.8% 27.7% 20.4% 48.1% 25.0% 0.0% 25.0% 100.0% 6	Mean Difference IV, Random, 95% CI -0.80 [-3.07, 1.47] -0.46 [-3.95, 3.03] -4.02 [-7.13, -0.91] -1.69 [-3.81, 0.43] -2.00 [-3.19, -0.81] -1.10 [-2.70, 0.50] -1.68 [-2.63, -0.72] -3.20 [-4.52, -1.88] 0.10 [-1.42, 1.62] -3.20 [-4.52, -1.88] -2.02 [-2.96, -1.08]	Mean Di N, Rando	fference m. 95% Cl

anti-inflammatory effects, neuroprotective effects, promotion of axonal regeneration, promotion of angiogenesis, and other poststroke processes (Fig. 7).^[42,43] Currently, the timing of stem cell infusion remains uncertain, and stem cell infusion is usually at the minimum dose in the safe range obtained from dose gradient experiments.^[44] The main methods of stem cell therapy are intravenous and arterial infusions. However, the optimal route of administration remains to be determined. Meanwhile, bone MSCs are the most commonly used stem cells in published studies.^[45] This may be due to their overall physiological characteristics, including easy access, sufficient autologous sources, low immunogenicity, and self-renewal.^[46,47] It is also the most efficient stem cell to produce exosomes, an important substance for stem cells to exert their effects.^[48] Exosomes are speculated to be able to transmit proteins, genetic information, and cytokines to target cells, thereby regulating the key physiological and pathological activities of target cells.^[49]

A recent meta-analysis of a clinical study on stem cells in the treatment of ischemic stroke revealed that the application of stem cells can improve neurological deficits and activities of daily living in patients with ischemic stroke; however, its benefits remain limited.^[50] Therefore, our meta-analysis further analyzed the correlation between stem cell therapy for ischemic stroke and the prognosis (neurological function recovery, quality of life, and mortality) of patients. All 13 studies included in the present analysis were RCTs, which are currently the highest-level .

	Ste	m Cell		Control			Mean Difference	Mean Difference
Study or Subgroup 3.1.1 MSCs	Mean	SD T	otal Mear	<u>1 SE</u>) Total	Weight	IV, Random, 95%	CI IV, Random, 95% CI
Bang 2005	62	20.8	10 42.	6 23.6	5 20	23.3%	19.40 [2.87, 35.	93]
Jaillard 2020	80.63	30.87	16 77.8	5 25.4	14	18.0%	2.77 [-17.38, 22.	92]
Xie 2016	59.55	20.67	12 53.	5 13.13	3 10	27.6%	6.05 [-8.20, 20.	30]
Subtotal (95% CI)			38		44	68.9%	9.74 [0.15, 19.3	33]
Heterogeneity: Tau ² =	1.09; Chi	i ² = 2.03,	df = 2 (P =	0.36); P	= 1%			2
Test for overall effect: .	Z=1.99 ((P = 0.05)					
3.1.2 MNCs								
Jin 2017	87.5	7.6	10 63.	3 18.9	10	31.1%	24.20 [11.57, 36.	83]
Prasad 2014	63.9	29.6	60 63.0	29.6	0 0	24 40/	Not estima	
Subioral (95% CI)	rlianhla		10		10	31.170	24.20 [11.57, 30.0	55]
Test for overall effect:	Z = 3.76 ((P = 0.00	02)					
Total (95% CI)			108		54	100.0%	14.22 [3.95, 24.4	48]
Heterogeneity: Tau ² =	46.62; CI	hi= 5.24	4, df = 3 (P	= 0.15);	1= 43%			
Test for overall effect:	Z = 2.71 ((P = 0.00)	(7)					-50 -25 0 25 5
Test for subaroup diffe	erences:	Chi ² = 3.	19 df = 1 (P = 0.07). I ² = 68.	7%		Favours (experimental) Favours (control)
<u> </u>	Sten	n Cell	Conti	ol		0	dds Ratio	Odds Ratio
Study or Subgroup	Event	s lota	Events	Total	Weight	M-H, F	Random, 95% Cl	M-H, Random, 95% Cl
3.2.1 MSCs								
Bang 2005		0 5	5 0	25			Not estimable	
Chung 2021		0 39	9 0	15			Not estimable	
Jaillard 2020		0 16	6 1	15	3.6%		0.29 [0.01, 7.76]	•
Lee 2010		4 16	5 21	36	22.6%		0.24 [0.06, 0.88]	
Xie 2016		0 12	2 0	10			Not estimable	
Subtotal (95% CI)		88	3	101	26.3%		0.25 [0.07, 0.83]	
Total events		4	22					
Heterogeneity: Tau ^a Test for overall effect	= 0.00; 0 t: Z = 2.2	Chi [#] = 0.1 6 (P = 0	01, df = 1 (.02)	(P = 0.9	1); I ≖ = 0'	%		
3.2.2 MNCs								
Bhasin 2016		0 10	0 0	10			Not estimable	
Bhatia 2018		1 10	2	10	5.8%		0.44 [0.03, 5.88]	
Jin 2017		1 10	1	10	4.6%	1	.00 (0.05, 18,57)	
Prasad 2014		5 59	3 5	60	23.2%		1.02 [0.28, 3.72]	
Subtotal (95% CI)		89)	90	33.6%		0.88 [0.30, 2.58]	
Total events		7	8					
Heterogeneity: Tau ²		$hi^2 = 0$	33 df = 20	P = 0.8	5) IF = 0	*		
Test for overall effect	t: Z = 0.2	3 (P = 0	.82)	u – 0.0	0/11 = 0			
3.2.3 Others								
Chen 2014		0 15	5 0	0			Not estimable	
Fang 2018-1		0 5	5 3	6	3.7%		0.09 [0.00, 2.35]	• •
Fang 2018-2		0 4	1 3	6	3.6%		0.11 [0.00, 2.94]	•
Hess 2017		5 65	5 9	61	29.2%		0.48 [0.15, 1.53]	
Savitz 2019		0 20	3 1	16	37%		0.18 (0.01. 4.56)	• • • • • • • • • • • • • • • • • • • •
Subtotal (95% CI)		118	3	89	40.2%		0.33 [0.12. 0.88]	
Total events		5	16		10			
Heterogeneity Tau?	= 0.00.0	$chi^2 = 1$	60 df= 3 (P=06	6) F = 0	*		
Test for overall effect	t: Z = 2.2	1 (P = 0)	.03)	0.0	-,, 0			
Total (95% CI)		295	5	280	100.0%		0.42 [0.23. 0.79]	•
Total events	1	6	46	STORE AND				7653
Heterogeneity Tauz	= 0.00.0	hi ² = 4	73 df = 9/	P = 0.7	q) ^z = 0	%		
Test for overall offeet	- 0.00, C	Q (P = 0	007)	u = 0.7	5),1 = 0	10		0.01 0.1 1 10 10
	2.0	-0						Equation Experimental Equation I controll

Figure 4. Meta-analysis (A) and sensitivity analysis (B) of the effects of stem cells on ischemic stroke, with National Institute of Health stroke scale.

evidence of evidence-based medicine on this topic.^[51] The results demonstrated that there were significant differences in the mRS score, NIHSS score, BI score, and mortality, favoring stem cell treatment. This result supports the notion that the use of stem cells can improve the prognosis and quality of life of patients with ischemic stroke.

Stem cells have been used in many preclinical studies and some clinical trials since their development, producing some encouraging results. However, stem cell therapy has not yet translated into clinical practice. Current clinical applications of stem cells have limitations including optimal cell source, preparation of autologous stem cells that fully meet transplantation conditions, dose, time window and route of transplantation, and monitoring and management of adverse events during stem cell transplantation.^[52] These limitations must be overcome to ensure the safety and efficacy of stem cells. Because of the safety



Figure 5. Meta-analysis of the effects of stem cells on all complications of ischemic stroke (A). Subgroup analysis of the effect of stem cells on complications of ischemic stroke (B).

risk associated with stem cell application and insufficient clinical data, stem cells should be considered carefully and be fully prepared by an experienced clinician.

Our study had several limitations. This study was based on a small number of clinical trials because stem cell therapy has recently made the jump from preclinical animal studies to an experimental clinical setting. Hence, the available literature on this topic is scarce. High heterogeneity existed in the NIHSS and BI outcomes. This may be due to the fact that the basic NIHSS score (3–30), gender (male > female), cerebral ischemia duration

Table 2

Complications reported in the studies included.

Author	Year	Cases	Complications (%)
Bang ^[24]	2005	1	Cellulitis (100%)
Bhasin ^[25]	2016	0	0
Bhatia ^[26]	2018	4	New infarct (25%), Death (75%)
Chen ^[27]	2014	0	0
Chung ^[28]	2021	3	Recurrent stroke or TIA (33.33%), Allergic reactions (33.33%), Systemic complications (33.33%)
Fang ^[29]	2018	7	Seizure (28.57%), Deep vein thrombosis (14.29%), Parkinson's syndrome (14.29%), Arrhythmia (14.29%), Recurrent stroke (14.29%), Cancer (14.29%)
Hess ^[30]	2017	123	Study drug-related (16.26%), Secondary infection (43.90%), Serious adverse events (37.40%)
Jaillard ^[31]	2020	41	Death (2.44%), Depression (4.88%), Recurrent ischemic stroke (4.88%), TIA (2.44%), Urinary tract infection (12.20%), Crytpogenic fever (2.44%), Algodystrophia (4.88%), Hip pain(2.44%), Humeral fracture (7.72%), Foot skin infection (2.44%), Epileptic seizures (26.83%), Deep lower limb venous thrombosis (2.44%), Pneumonia (12.20%), Gastrostomy (2.44%), Ankle sprain (2.44%), Atrial flutter (2.44%), Rotator cuff tear (2.44%), Kidney pain (2.44%)
Jin ^[35]	2017	25	Fever (8%), Pain in puncture site (80%), Pulmonary infection (4%), Death (8%)
Lee ^[32]	2010	47	Recurrent stroke (6.38%), Myocardial infarction or angina (6.38%), Peripheral artery occlusive disease (2.13%), Infection (pneumonia, urinary tract infection) (25.53%), Acute renal failure (2.13%), Liver enzyme elevation (6.38%), Systemic cancer (2.13%), Mass, benign (4.26%), Seizure (17.02%), Neuropyschological illness (27.66%)
Prasad ^[21]	2014	121	Haematological (24.79%), Hepatic (28.93%), Others (46.28)
Savitz ^[33]	2019	39	Mild (38.46%), Moderate (38.46%), Severe (23.07%)
Xie ^[34]	2016	0	0

TIA = transient ischemic attack.



(acute, subacute, chronic), stem cell types, stem cell injection dose, drug administration (intra-arterial injection, intravenous injection) and recovery time of the patients included in the studies differed. After the sensitivity analysis, the heterogeneity significantly decreased, but without any change to the significant difference in the overall effect. Stroke of different severity may be associated with different complications, which may also affect the evaluation of efficacy and safety. Different types of stroke may have different treatments other than stem cell therapy, which may affect clinical outcomes and should be a limitation of the present study. In addition, this study protocol was not registered before it started, and records identified from the database was relatively small, which was also a limitation of the present study.

Figure 7 mechanism diagram of stem cell therapy for ischemic stroke.



5. Conclusion

Stem cell therapy may reduce mortality and improve the neurological prognosis of ischemic stroke patients. However, due to the different types of stem cells used and the limited data in the reported studies, the safety of clinical applications of stem cells in patients with ischemic stroke must be carefully evaluated. Future randomized controlled trials with large sample sizes from controlled cell sources are warranted to validate this finding.

Author contributions

Conceptualization: Feng Zheng, Hao Yao. Data curation: Xiumei Guo, Chunhui Chen. Formal analysis: Wen Gao. Methodology: Yu Xiong, Chuhan Ke. Project administration: Xinyue Huang. Resources: Yu Xiong, Zhigang Pan. Software: Yu Xiong, Hanlin Zheng. Supervision: Weipeng Hu. Visualization: Hao Yao.

References

- Barthels D, Das H. Current advances in ischemic stroke research and therapies. Biochim Biophys Acta Mol Basis Dis. 2020;1866: 165260.
- [2] Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis. 2003;16:14–9.
- [3] Herpich F, Rincon F. Management of acute ischemic stroke. Crit Care Med. 2020;48:1654–63.
- [4] Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: present status and future perspectives. Int J Mol Sci. 2020;21:7609.
- [5] Tong DC. Intravenous rt-PA for stroke. Curr Med Res Opin. 2002;18(Suppl 2):s35–43.

- [6] Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: an overview of clinical and preclinical studies. Exp Neurol. 2021;335:113518.
- [7] Warach SJ, Dula AN, Milling TJ Jr. Tenecteplase thrombolysis for acute ischemic stroke. Stroke. 2020;51:3440–51.
- [8] Minnerup J, Wersching H, Teuber A, et al.; REVASK Investigators. Outcome after thrombectomy and intravenous thrombolysis in patients with acute ischemic stroke: a prospective observational study. Stroke. 2016;47:1584–92.
- [9] Silva GS, Nogueira RG. Endovascular treatment of acute ischemic stroke. Continuum (Minneap Minn). 2020;26:310–31.
- [10] Dimyan MA, Cohen LG. Neuroplasticity in the context of motor rehabilitation after stroke. Nat Rev Neurol. 2011;7:76–85.
- [11] Chavez LM, Huang SS, MacDonald I, et al. Mechanisms of acupuncture therapy in ischemic stroke rehabilitation: a literature review of basic studies. Int J Mol Sci. 2017;18:2270.
- [12] Xin H, Li Y, Liu Z, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells. 2013;31:2737–46.
- [13] Wanner IB, Deik A, Torres M, et al. A new in vitro model of the glial scar inhibits axon growth. Glia. 2008;56:1691–709.
- [14] Shan Y, Hu J, Lv H, et al. miR-221 exerts neuroprotective effects in ischemic stroke by inhibiting the proinflammatory response. J Stroke Cerebrovasc Dis. 2021;30:105489.
- [15] Cai G, Cai G, Zhou H, et al. Mesenchymal stem cell-derived exosome miR-542-3p suppresses inflammation and prevents cerebral infarction. Stem Cell Res Ther. 2021;12:2.
- [16] Su Y, Yuan J, Zhang F, et al. MicroRNA-181a-5p and microRNA-181a-3p cooperatively restrict vascular inflammation and atherosclerosis. Cell Death Dis. 2019;10:365.
- [17] Deng Y, Chen D, Gao F, et al. Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2. J Biol Eng. 2019;13:71.
- [18] Dong M, Xi G, Keep RF, et al. Role of iron in brain lipocalin 2 upregulation after intracerebral hemorrhage in rats. Brain Res. 2013;1505:86–92.
- [19] Xiong Y, Song J, Huang X, et al. Exosomes derived from mesenchymal stem cells: novel effects in the treatment of ischemic stroke. Front Neurosci. 2022;16:899887.

- [20] Bhasin A, Srivastava M, Bhatia R, et al. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med. 2012;8:181–9.
- [21] Prasad K, Sharma A, Garg A, et al.; InveST Study Group. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014;45:3618–24.
- [22] Zheng F, Dong Y, Xia P, et al. Is clipping better than coiling in the treatment of patients with oculomotor nerve palsies induced by posterior communicating artery aneurysms? A systematic review and meta-analysis. Clin Neurol Neurosurg. 2017;153:20–6.
- [23] Liu CW, Liu B, Ye W, et al. [Carotid endarterectomy versus carotid stenting: a prospective randomized trial]. Zhonghua Wai Ke Za Zhi. 2009;47:267–70.
- [24] Bang OY. Intravenous administration of autoserum-cultured autologous mesenchymal stem cells in ischemic stroke: a single center, randomized, open label, prospective, phase 3 study. 2012. Available at: https://www. cochranelibrary.com/central/doi/10.1002/central/CN-01614189/full.
- [25] Bhasin A, Srivastava MVP, Mohanty S, et al. Paracrine mechanisms of intravenous bone marrow-derived mononuclear stem cells in chronic ischemic stroke. Cerebrovasc Dis Extra. 2016;6:107–19.
- [26] Bhatia V, Gupta V, Khurana D, et al. Randomized assessment of the safety and efficacy of intra-arterial infusion of autologous stem cells in subacute ischemic stroke. AJNR Am J Neuroradiol. 2018;39:899–904.
- [27] Chen DC, Lin SZ, Chou DY, et al. Intracerebral implantation of autologous (CD34) in old ischemic stroke patients: aphase ii randomized controlled trial. Conference Abstract. Cerebrovasc Dis. 2014;38:7.
- [28] Chung JW, Chang WH, Bang OY, et al.; STARTING-2 Collaborators. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke. Neurology. 2021;96:e1012–23.
- [29] Fang J, Guo Y, Tan S, et al. Autologous endothelial progenitor cells transplantation for acute ischemic stroke: a 4-year follow-up study. Stem Cells Transl Med. 2019;8:14–21.
- [30] Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:360–8.
- [31] Jaillard A, Hommel M, Moisan A, et al.; (for the ISIS-HERMES Study Group). Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. Transl Stroke Res. 2020;11:910–23.
- [32] Lee JS, Hong JM, Moon GJ, et al.; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099–106.
- [33] Savitz SI, Yavagal D, Rappard G, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). Circulation. 2019;139:192–205.
- [34] Xie B, Gu P, Wang W, et al. Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy. Am J Transl Res. 2016;8:3241–50.

- [35] Jin Y, Ying L, Yu G, et al. Analysis of the long-term effect of bone marrow mononuclear cell transplantation for the treatment of cerebral infarction [Article]. Int J Clin Exp Med. 2017;10:3059–68.
- [36] Ghandehari K. Challenging comparison of stroke scales. J Res Med Sci. 2013;18:906–10.
- [37] Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5:603–12.
- [38] Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17:11–22.
- [39] Imam YZ, D'Souza A, Malik RA, et al. Secondary stroke prevention: improving diagnosis and management with newer technologies. Transl Stroke Res. 2016;7:458–77.
- [40] Zhang Z, Zou X, Zhang R, et al. Human umbilical cord mesenchymal stem cell-derived exosomal miR-146a-5p reduces microglial-mediated neuroinflammation via suppression of the IRAK1/TRAF6 signaling pathway after ischemic stroke. Aging (Albany NY). 2021;13:3060–79.
- [41] Li G, Xiao L, Qin H, et al. Exosomes-carried microRNA-26b-5p regulates microglia M1 polarization after cerebral ischemia/reperfusion. Cell Cycle. 2020;19:1022–35.
- [42] Yoo J, Kim HS, Hwang DY. Stem cells as promising therapeutic options for neurological disorders. J Cell Biochem. 2013;114:743–53.
- [43] Hu Z, Yuan Y, Zhang X, et al. Human umbilical cord mesenchymal stem cell-derived exosomes attenuate oxygen-glucose deprivation/ reperfusion-induced microglial pyroptosis by promoting FOXO3adependent mitophagy. Oxid Med Cell Longev. 2021;2021:6219715.
- [44] Levy ML, Crawford JR, Dib N, et al. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke. 2019;50:2835–41.
- [45] Duan S, Wang F, Cao J, et al. Exosomes derived from MicroRNA-146a-5p-enriched bone marrow mesenchymal stem cells alleviate intracerebral hemorrhage by inhibiting neuronal apoptosis and microglial M1 polarization. Drug Des Devel Ther. 2020;14:3143–58.
- [46] Tian T, Zhang HX, He CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137–49.
- [47] Kuang Y, Zheng X, Zhang L, et al. Adipose-derived mesenchymal stem cells reduce autophagy in stroke mice by extracellular vesicle transfer of miR-25. J Extracell Vesicles. 2020;10:e12024.
- [48] Cosenza S, Toupet K, Maumus M, et al. Mesenchymal stem cellsderived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. 2018;8:1399–410.
- [49] De Jong OG, Van Balkom BW, Schiffelers RM, et al. Extracellular vesicles: potential roles in regenerative medicine. Front Immunol. 2014;5:608.
- [50] Li Z, Dong X, Tian M, et al. Stem cell-based therapies for ischemic stroke: a systematic review and meta-analysis of clinical trials. Stem Cell Res Ther. 2020;11:252.
- [51] Pocock SJ, McMurray JJ, Collier TJ. Making sense of statistics in clinical trial reports: part 1 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015;66:2536–49.
- [52] Zhou L, Zhu H, Bai X, et al. Potential mechanisms and therapeutic targets of mesenchymal stem cell transplantation for ischemic stroke. Stem Cell Res Ther. 2022;13:195.